Table 1.
Characteristics of the patients. Time-to-Chemotherapy (TTC) before and after 6 weeks.
| Variables | ≤6 Weeks | >6 Weeks | p | ||
|---|---|---|---|---|---|
| n = 233 | n = 116 | n = 117 | |||
| Age (years) | 59 (±12) | 58 (±12) | 60 (±12) | 0.41 | |
| BMI (kg/m2) | 24.58 (±4.88) | 24.09 (±4.79) | 25.08 (±4.94) | 0.13 | |
| Parity | 1.64 (±1.42) | 1.798 (±1.52) | 1.482 (±1.3) | 0.1 | |
| Mutation | BRCA 1 | 12 (5.1%) | 8 (6.8%) | 13 (11.1%) | 0.14 |
| BRCA 2 | 5 (2.1%) | 1 (3.4%) | 0 | ||
| Hypertension | 42 (24.6%) | 20 (22.5%) | 22 (26.8%) | 0.51 | |
| Diabetes | 10 (6.2%) | 6 (7.1%) | 4 (5.2%) | 0.85 | |
| Smoking | 12 (8.5%) | 5 (6.8%) | 7 (10.1%) | 0.48 | |
| Histologic type | Serous | 155 (70.1%) | 77 (74.5%) | 80 (66.1%) | 0.71 |
| Endometrioid | 37 (16.7%) | 15 (14.2%) | 22 (19.1%) | ||
| Clear Cell | 23 (10.4%) | 10 (9.7%) | 13 (10.7%) | ||
| Mucinous | 6 (2.7%) | 2 (1.9%) | 4 (3.3%) | ||
| Grade | 1 | 21 (67.7%) | 9 (75%) | 12 (63.2%) | 0.23 |
| 2 | 7 (22.6%) | 1 (8.3%) | 6 (31.6%) | ||
| 3 | 3 (9.7%) | 2 (16.7%) | 1 (5.3%) | ||
| Lymphovascular space involvement | Yes | 35 (43.8%) | 22 (46.8%) | 13 (39.4%) | 0.51 |
| Stage | Early | 69 (29.6%) | 89 (76.7%) | 75 (64.1%) | 0.035 |
| Advanced | 164 (70.4%) | 27 (23.3%) | 42 (35.9%) | ||
| FIGO Stage | I | 56 (24%) | 18 (15.5%) | 38 (32.5%) | 0.0092 |
| II | 17 (7.2%) | 11 (9.5%) | 6 (5.1%) | ||
| III | 141 (60.5%) | 74 (63.8%) | 67 (57.3%) | ||
| IV | 19 (8.1%) | 13 (11.2%) | 6 (5.1%) | ||
| Type of recurrence | Lymph node | 16 (16.7%) | 9 (17%) | 7 (16.3%) | 0.22 |
| Peritoneal Carcinomatosis | 63 (65.6%) | 37 (69.8%) | 26 (60.5%) | ||
| Metastasis | 9 (9.4%) | 2 (3.8%) | 7 (16.3%) |
FIGO: International Federation of Gynecology and Obstetrics.